Pancreatic Cancer Research

ResearcherShandong University of Traditional Chinese MedicineActive in the last 2 years

Bin Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0854-7871; OpenAlex author ID A5051440995. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2017: 2 papers · 2018: 7 papers · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 4 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 19

  1. Baicalein disrupts TGF-β-induced EMT in pancreatic cancer by FTO-dependent m6A demethylation of ZEB1. Last author DOI 10.1016/j.bbamcr.2025.119969↗
  2. Corrigendum to: "Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death" [Biomed. Pharmacother. 153 (2… Co-author DOI 10.1016/j.biopha.2023.115879↗
  3. Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. Co-author DOI 10.1016/j.biopha.2022.113511↗
  4. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.matbio.2022.11.002↗
  5. UHMK1 Is a Novel Marker for Personalized Prediction of Pancreatic Cancer Prognosis. Co-author DOI 10.3389/fonc.2022.834647↗
  6. Progress and prospects for use of cellular immunotherapy in pancreatic cancer. Last author DOI 10.4103/jcrt.jcrt_976_21↗
  7. Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression. First author DOI 10.3390/cancers13040827↗
  8. Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer. Co-author DOI 10.3390/cancers13194770↗
  9. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  10. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  11. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Co-author DOI 10.1016/j.csbj.2018.10.006↗
  12. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  13. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  14. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. First author DOI 10.1155/2018/9482018↗
  15. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  16. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Co-author DOI 10.3892/ijo.2018.4573↗
  17. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner. Co-author DOI 10.3892/or.2018.6696↗
  18. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  19. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingrid Herr · 7 shared papers, 2021–2025 · strength 1.20
  2. Qingyong Ma · 11 shared papers, 2017–2019 · strength 0.81
  3. Liang Cheng · 11 shared papers, 2017–2019 · strength 0.81
  4. Michael Schaefer · 4 shared papers, 2021–2025 · strength 0.77
  5. Xuefeng An · 5 shared papers, 2021–2023 · strength 0.74
  6. Weikun Qian · 10 shared papers, 2017–2019 · strength 0.74
  7. Cancan Zhou · 10 shared papers, 2017–2019 · strength 0.73
  8. Junyu Cao · 9 shared papers, 2017–2019 · strength 0.66
  9. Lian Zhao · 3 shared papers, 2022–2025 · strength 0.59
  10. Zhengdong Jiang · 8 shared papers, 2017–2019 · strength 0.57
  11. Yiqiao Luo · 4 shared papers, 2021–2022 · strength 0.56
  12. Jiguang Ma · 7 shared papers, 2017–2019 · strength 0.52
  13. Wanxing Duan · 7 shared papers, 2017–2019 · strength 0.50
  14. Ke Chen · 7 shared papers, 2017–2019 · strength 0.49
  15. Liankang Sun · 6 shared papers, 2017–2019 · strength 0.43
  16. Kangtao Wang · 2 shared papers, 2021–2025 · strength 0.41
  17. Li Liu · 3 shared papers, 2021–2022 · strength 0.38
  18. Qinhong Xu · 4 shared papers, 2018–2019 · strength 0.30
  19. Chen Gong · 1 shared paper, 2025 · strength 0.28
  20. Jie Li · 4 shared papers, 2017–2018 · strength 0.27
  21. Li Liu · 1 shared paper, 2023 · strength 0.19
  22. Jing Tian · 1 shared paper, 2022 · strength 0.17
  23. Zhiyong Zhang · 1 shared paper, 2022 · strength 0.17
  24. Li Liu · 1 shared paper, 2022 · strength 0.16
  25. Erxi Wu · 2 shared papers, 2019 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.